CONSUN PHARMAC.GR.HD -10

CONSUN PHARMAC.GR.HD -10

C1P · F · Healthcare / Drug Manufacturers - Specialty & Generic

1.75EUR+0.00 (0.00%)

Price History

Full chart

Market Stats

Previous Close1.75
Open1.73
Day Range1.73 – 1.75
52-Week Range1.30 – 2.06
Volume0
Market Cap1.33B
P/E (TTM)8.83
Forward P/E0.00
EPS0.18
Dividend Yield5.42%
Beta0.48
50-Day Avg1.48
200-Day Avg1.63

About

Consun Pharmaceutical Group Limited, together with its subsidiaries, produces and sells pharmaceutical products in Mainland China. It operates through two segments, Consun Pharmaceutical and Yulin Pharmaceutical. The company offers uremic clearance granules for chronic renal failure; Yishen Huashi particles for proteinuria; TCM to treat diabetic kidney disease; Gadopentetate Dimeglumine injections for nervous centralis, stomach, chest, pelvic cavity, and extremities, as well as for renal function assessment; Iopamidol injections for neuroradiology, angiography, and urography; and ultrasonic microbubble contrast agent products. It also provides Yuanli Kang, an iron-dextrin oral solution; Yibao Yuan, an erythromycin estolate suspension; Yuantong Ning, a cetirizine hydrochloride oral solution; Zhixueling capsules to treat hysteromyoma bleeding, prolonged lochiorrhea, intermenstrual bleeding, bleeding after use of a contraceptive ring, hemorrhoidal bleeding, and epistaxis; Gyn Antidysmenorrheic tablets for irregular menstruation, period during perimenopause, and abdominal pain during menstruation due to hepatic depression and blood deficiency; and Antibacterial Fujie lotion to treat staphylococcus aureus, candida albicans, and escherichia coli in the feminine vaginal. In addition, the company offers bone-setting liquid; Yunxiang analgesic tincture to treat rheumatism, common cold, headache, stomachache, cardiodynia, and pain in the gastral cavity and chilblain; Sanqi Chuangchun capsules for activating blood circulation and dispersing blood stasis; Shiduqing capsules and tablets, and Paeonol ointment for skin disease; hepatobiliary products, such as Jigucao, Compound Jigucao, and Qinggan tablets, as well as Jigucao Ganyan and Wujun Zhidan granules; and gastroenterology medicines, tonics, and other medicines. Consun Pharmaceutical Group Limited was founded in 1997 and is headquartered in Guangzhou, the People's Republic of China.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOMr. Meng An
  • Employees2.85K
  • Headquarters71, Dongpeng Avenue, Guangzhou, China, Germany
  • Websitehttps://chinaconsun.com

Leadership

  • Mr. Meng AnCEO & Executive Chairman · b. 1971
  • Ms. Yujun ChenChief Financial Officer · b. 1980
  • Prof. Quan ZhuChief Scientist & Non-Executive Director · b. 1940
  • Mr. Yuk Chuen YoungExecutive Director · b. 1998
  • Lei ZhouAssistant President
  • Mr. Haien GaoCompany Secretary · b. 1969
  • Mr. Guorong GuoChairman & GM of Guangxi Yulin Pharmaceutical Group Co. Ltd
  • Ms. Lianhui ChenChairman & GM of Consun Pharmaceutical (Horgos) Co., LTD.

Financials

Income Statement

Currency: CNY2021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue2.04B2.34B2.59B2.97B3.42B
Growth (%)-+14.43%+10.71%+14.56%+15.17%
Cost of Revenue517.32M576.74M668.44M725.13M750.24M
Gross Profit1.53B1.76B1.92B2.24B2.67B
Gross Margin74.70%75.35%74.19%75.56%78.05%
Operating Expense875.02M1.04B1.11B1.28B1.51B
Operating Income652.31M719.46M810.03M962.77M1.15B
Operating Margin31.90%30.75%31.27%32.45%33.72%
EBITDA-833.68M963.06M1.11B1.27B
EBITDA Margin-35.63%37.18%37.37%37.09%
Net Income590.17M682.91M784.53M910.46M1.08B
Net Income Margin28.86%29.19%30.29%30.68%31.55%
Interest Expense12.90M10.93M21.26M24.89M4.36M
Interest Expense % of Total Revenue0.63%0.47%0.82%0.84%0.13%

Balance Sheet

Currency: CNY2021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets4.36B4.89B5.51B5.85B6.41B
Total Liabilities1.45B1.45B1.59B1.46B1.57B
Total Equity2.62B3.15B3.63B4.10B4.54B
Cash2.20B2.45B2.75B2.91B1.23B

Cash Flow

Currency: CNY2021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow725.54M947.68M818.97M1.09B1.21B
Capital Expenditure98.25M51.59M52.56M109.00M68.48M
Free Cash Flow627.29M896.09M766.41M977.99M1.14B
Dividends Paid198.08M127.49M326.25M680.54M498.39M
FCF to OCF86.46%94.56%93.58%89.97%94.35%
Dividend Paid to FCF31.58%14.23%42.57%69.59%43.59%

Key Statistics & Ratios

Market Cap1.33B
Enterprise Value845.65M
Trailing P/E8.83
Forward P/E0.00
Price / Sales0.37
Price / Book2.08
EPS0.18
Book Value0.7516
Revenue (TTM)3.63B
Gross Profit (TTM)2.91B
EBITDA1.36B
Profit Margin32.34%
Operating Margin37.19%
Return on Equity24.40%
Return on Assets12.58%
Shares Outstanding837.84M
Shares Float456.13M
Beta0.48
Dividend Yield5.42%
Dividend Rate0.09
Payout Ratio46.92%

Dividends

20262×
0.04Sep 8, 20260.04Jun 9, 2026
20252×
0.04Sep 4, 20250.03Jun 10, 2025
20242×
0.03Sep 5, 20240.07Jun 11, 2024
20234×
0.02Sep 7, 20230.15Sep 6, 20230.03Jun 8, 20230.26Jun 7, 2023
20221×
0.02Jun 2, 2022
20213×
0.01Sep 8, 20210.09Sep 1, 20210.02May 28, 2021
20202×
0.01Sep 2, 20200.01Jun 5, 2020
20193×
0.01Sep 2, 20190.02Jun 6, 20190.17May 31, 2019
20182×
0.01Jun 5, 20180.09Jun 1, 2018
20173×
0.01Sep 6, 20170.01Jun 2, 20170.01May 5, 2017